AgingResearch.NewsJoin free
AHA Scientific Sessions 2026 Abstract

Diabetes drugs linked to lower risk of muscle wasting

Users of one drug class had a 23–29% lower relative risk than metformin users over 12 months in an observational analysis.

Paper by Moiz Lakhani, Angela Kwan · Harvard Univ · Univ of Toronto
Muscle cutaways show thick, tightly packed dark blue-green fibers beside thinner gray fibers, with small upright groups of people nearby.

Our read

Interventions
Studied:
Cohort study of 871,884 adults with type 2 diabetes, 12 months, against metformin users
What changed:
Incident muscle atrophy risk was 23-29% lower with GLP-1-based therapies than with metformin
The catch:
Outcomes were diagnosis codes; changes in muscle mass or quality were not measured
Why it’s aging research:
It studies an intervention with evidence of extending healthy life.

Editor of record: Boris Djordjevic · AgingResearch.News

Paper
Follow @agingbrief

Adults with type 2 diabetes were included in a retrospective observational analysis of 871,884 matched patients across three drug comparisons. The design mimicked randomized trials but did not randomly assign medicines. Researchers matched new users on 16 factors, including age, sex and health conditions, and tracked new muscle-wasting diagnoses for 12 months.

Diabetes medicines that mimic the hormone glucagon-like peptide-1 were associated with lower risk than metformin. Semaglutide, one medicine in that class, was also associated with lower risk than metformin. Tirzepatide and semaglutide had comparable risks; the range of likely values included no difference. The authors called for prospective trials with objective measurements of body composition.

Why it matters

Muscle wasting predicts disability and death in people with type 2 diabetes. The findings bear on concerns about loss of lean tissue during weight loss with these medicines.

Caveats

People prescribed these drugs may have differed in unmeasured health characteristics from metformin users despite matching. The conference abstract reported diagnosis-based outcomes in adults with type 2 diabetes, not measured changes in muscle mass or quality.

Comments

Be the first to comment.

Related